{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:53:52Z","timestamp":1775908432838,"version":"3.50.1"},"reference-count":18,"publisher":"American Society of Consultant Pharmacists","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Consult Pharm"],"published-print":{"date-parts":[[2014,5,1]]},"DOI":"10.4140\/tcp.n.2014.335","type":"journal-article","created":{"date-parts":[[2014,5,21]],"date-time":"2014-05-21T21:13:34Z","timestamp":1400706814000},"page":"335-346","source":"Crossref","is-referenced-by-count":28,"title":["A Review of the Efficacy and Safety of Canagliflozin in Elderly Patients with Type 2 Diabetes"],"prefix":"10.4140","volume":"29","author":[{"given":"Lindsey K.","family":"Elmore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Baggett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica W.","family":"Skelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"key":"1","unstructured":"Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. Available at http:\/\/www.cdc.gov\/diabetes\/pubs\/factsheet11.htm. Accessed October 8, 2013. <a target=\"_blank\" href='http:\/\/www.cdc.gov\/diabetes\/pubs\/factsheet11.htm'>http:\/\/www.cdc.gov\/diabetes\/pubs\/factsheet11.htm<\/a>"},{"key":"2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36 Suppl 1:S11-S66.","DOI":"10.2337\/dc13-S011"},{"key":"3","unstructured":"Kirkman MS. Diabetes in older adults: a consensus report. J Am Geriatr Soc 2012:1-15. Available at http:\/\/www.americangeriatrics.org\/search\/?cx=008664580565903273424%3Auo2vk7ffzna&cof=FORID%3A10&ie=UTF-8&q=eldery+adults+age+range&sa=%C2%A0. Accessed September 5, 2013. <a target=\"_blank\" href='http:\/\/www.americangeriatrics.org\/search\/?cx=008664580565903273424%3Auo2vk7ffzna&cof=FORID%3A10&ie=UTF-8&q=eldery+adults+age+range&sa=%C2%A0'>http:\/\/www.americangeriatrics.org\/search\/?cx=008664580565903273424%3Auo2vk7ffzna&cof=FORID%3A10&ie=UTF-8&q=eldery+adults+age+range&sa=%C2%A0<\/a>"},{"key":"4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","article-title":"Efficacy and safety of CAN treatment in older subjects with type 2 diabetes mellitus: a randomized trial","volume":"41","author":"B Bode","year":"2013","journal-title":"Hosp Pract"},{"key":"5","unstructured":"U.S. FDA Approves Invokana (CAN) for the Treatment of Adults with Type 2 Diabetes. Johnson and Johnson Web site. Updated June 25, 2013. Available at http:\/\/www.jnj.com\/news\/all\/us-fda-approves-invokana-CAN-for-the-treatment-of-adults-with-type-2-diabetes. Accessed June 24, 2013. <a target=\"_blank\" href='http:\/\/www.jnj.com\/news\/all\/us-fda-approves-invokana-CAN-for-the-treatment-of-adults-with-type-2-diabetes'>http:\/\/www.jnj.com\/news\/all\/us-fda-approves-invokana-CAN-for-the-treatment-of-adults-with-type-2-diabetes<\/a>"},{"key":"6","first-page":"313","article-title":"Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes","volume":"5","author":"Y Kim","year":"2012","journal-title":"Diabetes Metab Syndr Obes"},{"key":"7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of CAN in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"J-F Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"8","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebocontrolled study","volume":"36","author":"D Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"9","volume-title":"Efficacy and safety of CAN, an inhibitor of sodium glucose co-transporter 2, added on to insulin therapy with or without oral agents in type 2 diabetes","author":"D Matthews","year":"2012"},{"key":"10","volume-title":"CAN in subjects with type 2 diabetes mellitus inadequately controlled on sulfonylurea monotherapy: a CANVAS substudy","author":"G Fulcher","year":"2013"},{"key":"11","unstructured":"INVOKANA\u2122 [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2013. Available at http:\/\/www.invokanahcp.com\/prescribing-information.pdf. Accessed October 8, 2013. <a target=\"_blank\" href='http:\/\/www.invokanahcp.com\/prescribing-information.pdf'>http:\/\/www.invokanahcp.com\/prescribing-information.pdf<\/a>"},{"key":"12","unstructured":"Canagliflozin. In Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc.; updated August 1, 2013. Available at http:\/\/www.crlonline.com.ezproxy.samford.edu\/lco\/action\/doc\/retrieve\/docid\/patch_f\/4230722. Accessed October 21, 2013. <a target=\"_blank\" href='http:\/\/www.crlonline.com.ezproxy.samford.edu\/lco\/action\/doc\/retrieve\/docid\/patch_f\/4230722'>http:\/\/www.crlonline.com.ezproxy.samford.edu\/lco\/action\/doc\/retrieve\/docid\/patch_f\/4230722<\/a>"},{"key":"13","unstructured":"Formulary decision highlights: June 12, 2013. GroupHealth Web site. Available at https:\/\/provider.ghc.org\/open\/providerCommunications\/highlights\/june-2013.pdf. June 2013. Accessed August 9, 2013. <a target=\"_blank\" href='https:\/\/provider.ghc.org\/open\/providerCommunications\/highlights\/june-2013.pdf'>https:\/\/provider.ghc.org\/open\/providerCommunications\/highlights\/june-2013.pdf<\/a>"},{"key":"14","unstructured":"2012-2013 3-tier formulary guide. BlueCrossBlueShield Association Web site. Available at https:\/\/www.excellusbcbs.com\/wps\/wcm\/connect\/1786b4d6-ab4e-4844-8b9696b5a929952a\/Excellus+3-tier+ formulary+WEB+7.1.13pdf?MOD=AJPERES&CACHEID=1786b4d6-ab4e-4844-8b9696b5a929952a. Accessed August 9, 2013. <a target=\"_blank\" href='https:\/\/www.excellusbcbs.com\/wps\/wcm\/connect\/1786b4d6-ab4e-4844-8b9696b5a929952a\/Excellus+3-tier+ formulary+WEB+7.1.13pdf?MOD=AJPERES&CACHEID=1786b4d6-ab4e-4844-8b9696b5a929952a'>https:\/\/www.excellusbcbs.com\/wps\/wcm\/connect\/1786b4d6-ab4e-4844-8b9696b5a929952a\/Excellus+3-tier+ formulary+WEB+7.1.13pdf?MOD=AJPERES&CACHEID=1786b4d6-ab4e-4844-8b9696b5a929952a<\/a>"},{"key":"15","article-title":"California Healthcare Foundation\/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus","volume":"51","author":"AF Brown","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of CAN versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"WT Cefalu","year":"2013","journal-title":"The Lancet"},{"key":"17","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/dom.12149","article-title":"Efficacy and safety of CAN in Japanese patients with type 2 diabetes: a randomized, double-blind, placebocontrolled, 12-week study","volume":"15","author":"N Inagaki","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"18","unstructured":"Chau E. A Paradigm Shift in Diabetes Therapy\u2014Dapagliflozin and Other SLGT-2 Inhibitors. Discov Med 2011;11:255-63. Available at http:\/\/www.discoverymedicine.com\/Edward-C-Chao\/2011\/03\/23\/a-paradigmshift-in-diabetes-therapy-dapagliflozin-and-other-sglt2-inhibitors\/. Accessed November 4, 2013. <a target=\"_blank\" href='http:\/\/www.discoverymedicine.com\/Edward-C-Chao\/2011\/03\/23\/a-paradigmshift-in-diabetes-therapy-dapagliflozin-and-other-sglt2-inhibitors\/'>http:\/\/www.discoverymedicine.com\/Edward-C-Chao\/2011\/03\/23\/a-paradigmshift-in-diabetes-therapy-dapagliflozin-and-other-sglt2-inhibitors\/<\/a>"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T09:37:27Z","timestamp":1498124247000},"score":1,"resource":{"primary":{"URL":"http:\/\/openurl.ingenta.com\/content\/xref?genre=article&issn=0888-5109&volume=29&issue=5&spage=335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5,1]]}},"alternative-id":["0888-5109(20140501)29:5L.335;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2014.335","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5,1]]}}}